Shots: The P-III M15-736 Study evaluates the efficacy, safety & tolerability of ABBV-951 to levodopa/carbidopa in 130 adult patients with advanced PD across 80 sites globally The study met its […]readmore
Shots: The company has initiated a P-III ESLIM-01 trial to evaluate the efficacy and safety of HMPL-523 in 180 adult patients with ITP. The study is based on the results […]readmore
Shots: The P-III HELIOS-A study evaluate vutrisiran (25mg, SC, q3mos.) vs patisiran (0.3 mg/kg, IV, q3w) in a ratio (3:1) in 164 patients with hATTR amyloidosis with polyneuropathy at 57 […]readmore
Shots: The P-III study evaluate the efficacy, safety & immunogenicity of BCD-021 (q3w for 6 cycles) vs Avastin + paclitaxel & carboplatin in 357 patients with stage IIIB or IV […]readmore
Shots: The 2 P-III ILLUMINATE SWITCH A & B trials evaluate doravirine/islatravir (100/0.75mg, qd, PO) in a ratio (1:1) in 672 & 641 patients with HIV-1 who are virologically suppressed […]readmore
Shots: The P-III CANOPY-1 trial evaluates canakinumab (ACZ885) + pembrolizumab + platinum-based doublet CT vs PBO + pembrolizumab + CT in patients with LA or metastatic NSCLC The trial did […]readmore
Shots: The second P-III trial evaluates the efficacy and safety of Dupixent (300mg weekly) vs PBO in 240 patients aged ≥12yrs. with EoE for 24wks. The trial met its co-primary […]readmore
Shots: The P-III ECZTRA 6 trial evaluates the efficacy & safety of tralokinumab (150/300mg, q2w) as monothx. vs PBO in 301 patients aged 12-17yrs. with mod. to sev. AD who […]readmore
Shots: The P-III VANISH-303 evaluates ibrexafungerp vs PBO in patients with VVC & P-II DOVE studies assess ibrexafungerp vs fluconazole for the same indication. The results were published in America’s […]readmore
Shots: The P-III trial evaluates a booster dose of COVID-19 vaccine (30µg) in a ratio (1:1) in 10000+ individuals aged ≥16yrs. with COVID-19 who previously received the primary two-dose series […]readmore
Copyright © 2020 Digiqole. All Right Reserved.